Schema-Root.org logo

 

  cross-referenced news and research resources about

 Dutch biotechnology company Galapagos

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Wed. April 17, 2019

-
... on shares of Galapagos in a research note on Sunday, October 29th. One research analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has an average rating of “Buy” and an average price target of $111.00.
Galapagos NV logo Zacks Investment Research cut shares of Galapagos (NASDAQ:GLPG) from a hold rating to a strong sell rating in a research note ... rating and seven have given a buy rating to the company. Galapagos currently has a consensus rating of Buy and an average target price of $111.00.

Finally, ValuEngine lowered shares of Galapagos from a “hold” rating to a “sell” rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the company. Galapagos presently has a consensus rating of ...
Finally, ValuEngine downgraded Galapagos from a hold rating to a sell rating in a report on Friday, December 1st. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of ...
Finally, Nomura boosted their price target on Galapagos from $108.00 to $124.00 and gave the company a “buy” rating in a report on Friday, August 11th. Two research analysts have rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the company. Galapagos ...
Biotech company Galapagos has opted to co-promote filgotinib with its partner Gilead Sciences should the drug be approved in Europe, according to a press release. Filgotinib is an investigational oral Janus kinase 1 (JAK1)-selective inhibitor under evaluation in Crohn's disease, ulcerative colitis and ...

... Galapagos in a research note on Sunday, October 29th. Two equities research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have given a buy rating to the company. Galapagos currently has an average rating of “Hold” and a consensus price target of $111.00.
Headlines about Galapagos (NASDAQ:GLPG) have been trending somewhat positive on Saturday, according to Accern. ... a sell rating, three have given a hold rating and six have assigned a buy rating to the company. Galapagos has a consensus rating of “Hold” and an average target price of $111.00.
Recently, the company consolidated its CAR-T portfolio with the acquisition of Cell Design Labs. Although we like the Kite acquisition, we believe it would take a few years before the CAR-T franchise begins to have a positive impact on GILD's financials. This is something Meyers also notes in his recent ...
In a previous note to my subscribers, I said that Galapagos NV (NASDAQ:GLPG) is a strong buy after Celgene's dramatic failure in Crohn's Disease or CD, because its lead candidate filgotinib is now the most advanced drug in anybody's CD pipeline. The Celgene (NASDAQ:CELG) drug was thought to ...
The company is seeking approval in people with CF aged 12 and older who have two copies of the F508del mutation or one F508del mutation and one ... Belgian company Galapagos NV GLPG and AbbVie, Inc. ABBV are also developing triple CFTR combination therapy for CF, which may pose a threat to ...
Finally, BidaskClub raised Galapagos NV from a “sell” rating to a “hold” rating in a report on Thursday, August 17th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Galapagos NV currently has a consensus rating of “Buy” and a consensus target price of ...
Galapagos NV (NASDAQ:GLPG) – Stock analysts at Jefferies Group cut their FY2017 EPS estimates for shares of Galapagos in a report released on ... and seven have assigned a buy rating to the company. Galapagos presently has an average rating of “Hold” and a consensus target price of $111.00.
Finally, ValuEngine lowered shares of Galapagos from a hold rating to a sell rating in a research report on Friday, December 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company. Galapagos currently has a ...
Galapagos NV (NASDAQ:GLPG) was the recipient of a significant ... a buy rating to the company. Galapagos NV presently has an average ...
Investors also assessed a large stream of business results. ... Biotech company Galapagos lost 0.9 percent of stock market value after it ...
BTIG Research reiterated their buy rating on shares of Galapagos NV ... a buy rating to the company. Galapagos NV currently has an average ...

Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Galapagos NV has an ...
Galapagos NV posted sales of $32.38 million in the same quarter last ... a buy rating to the company. Galapagos NV presently has an average ...
Notably, the company had posted a loss of 1 cent in the year-ago quarter ... Belgian company, Galapagos NV GLPG and AbbVie, Inc. ABBV are ...
Two investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Galapagos NV presently has ...
The website allows for internet bookings and also displays in-depth information from local experts on each itinerary, with data on packages, perks and details into the company's Galapagos program. Sailings in the region are open through 2019. Vacation ...
One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and seven have issued a buy rating to the company. Galapagos NV presently has a consensus rating of Buy and an average target price of $72.50.
One investment analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Galapagos NV currently has a consensus rating of Hold and a consensus price target of $66.40. Shares of ...
Researchers conducting a Phase 1 study for cystic fibrosis (CF) have dosed their first healthy volunteer with a combination of the novel drugs GLPG2222 (a corrector) and GLPG2451 (a potentiator), the Belgian company Galapagos announced.
They set a "hold" rating and a $65.00 price target for the company. One analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. Galapagos NV presently has an average rating of ...
... November 30th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the company. Galapagos NV presently has a consensus rating of "Hold" and a consensus price target of $66.75.
Telecoms company Altice is the day's strongest performer to date with a gain of 2.08%. The company announced last week that it was considering an IPO to spin off its U.S.
Digital security company Gemalto is up 2.44%. The day's only real fallers are pharmaceuticals research company Galapagos, down 1.61% and food and nutritional supplements company Koninklijke DSM. And finally, to Stockholm, where the OMX 30 is flat, ...
The stock price of NASDAQ-listed Belgian company Galapagos NV ADR (GLPG) started soaring mid-September onwards amid rumors of the company being a possible takeover target by Gilead Sciences Inc. (GILD). Following a 10-day long rally which ...
Leerink Partners believe that the recent release of positive data related to Fitzroy could provide a significant boost to Gilead Sciences, Inc.'s (NASDAQ:GILD) research and development department.
GSEP worked collaboratively with the local utility company, Galapagos Electricity Utility, financial and environmental regulatory agencies and national and United Nations ministries to develop supportive public policies and tariffs.
Cowen and Company restated a "buy" rating on shares of Galapagos NV in a report on Saturday, April 30th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Galapagos NV has a consensus rating of ...
Belgian biotech company Galapagos NV (NASDAQ:GLPG) may be one of the most important drugmakers you haven't heard of yet.
According to a press release, Galapagos is starting a randomized, double-blind placebo-controlled Phase 1 trial to study the company's second potentiator compound, GLPG2451. The study will test a range of doses in healthy volunteers from the ...
Finally, Goldman Sachs cut Galapagos NV from a buy rating to a neutral rating in a research report on Monday, January 25th.
When the share price of Belgo-Dutch company Galapagos shot up 20% on its first NASDAQ trading day thanks to a promising rheumatism drug, CEO Onno van de Stolpe was both euphoric and realistic: "Obviously some [research] programmes will not be ...
... Thursday, December 17th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. Galapagos NV has an average rating of "Buy" and a consensus price target of $67.20.
In addition to its market leading HIV franchise, the company has a deep pipeline outside of HCV and HIV. In this article, we take a look at the other drugs delivering some $2 billion in annual sales, as well as the company's two main focus areas ...
Belgian biotech company Galapagos (Euronext: GLPG) said its drug candidate to treat bowel disease ulcerative colitis failed to achieve efficacy endpoints in mid-stage trials and it will discontinue the trials for that disease.
Belgian biotech company Galapagos has hit a huge roadblock after one of its promising new bowel medications turned out discouraging results in its phase I trial.
The Galapagos deal works like this: Gilead is paying Galapagos $725 million upfront to license filgotinib -- including a $425 million equity investment in Galapagos, which means Gilead will own around 15% of the company. Galapagos can earn another $1 ...
Belgian biotech company Galapagos (Euronext: GLPG) said its drug candidate to treat bowel disease ulcerative colitis failed to achieve efficacy endpoints in mid-stage trials and it will discontinue the trials for that disease.
Belgian biotech company Galapagos has hit a huge roadblock after one of its promising new bowel medications turned out discouraging results in its phase I trial.
The Galapagos deal works like this: Gilead is paying Galapagos $725 million upfront to license filgotinib -- including a $425 million equity investment in Galapagos, which means Gilead will own around 15% of the company. Galapagos can earn another $1 ...
... investors had paid when the companies were still private. Let's take a look at some of the market freshmen of 2015.
The most profitable IPOs were Belgian-Dutch bio-tech company Galapagos (Nasdaq) and the oil company Euronav (New York Stock Exchange), which raised 241 million dollars and 229 million dollars respectively.
One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company. Galapagos NV currently has a consensus rating of Buy and an average price target of $63.25.


 

news and opinion


 


 


 


 


schema-root.org

     galapagos

Biotechnology:
     galapagos
     genentech

cross-references for
galapagos:

Galapagos company